HOHannah Oppenheimer

Hannah Oppenheimer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hannah Oppenheimer has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sex differences in polygenic risk for sex-biased brain disorders: Associations with diagnostic status and brain age gap

    by Arielle Crestol, Dennis van der Meer, Nadine Parker, Ann-Marie G. de Lange, Espen Hagen, Hannah Oppenheimer, Stener Nerland, Édith Breton, Christian K. Tamnes, Ole A. Andreassen, et al.

  • Open Access

    Joint contributions of genetic risk and pubertal maturation to internalizing symptoms in adolescents

    by Arielle Crestol, Niamh MacSweeney, Elleke Tissink, Elvisha Dhamala, Hannah Oppenheimer, Lars T. Westlye, Ole A. Andreassen, Ingrid Agartz, Christian K. Tamnes, Claudia Barth

    Adolescence is a key developmental period during which the onset of puberty coincides with a rise in risk for internalizing psychopathology, with higher symptom burden in females. While genetic risk for internalizing phenotypes is associated with adolescent-onset depression, it remains unclear whether these associations vary by pubertal maturation or sex. In this longitudinal study across seven timepoints, we examined whether pubertal timing, pubertal tempo, and sex moderate associations between polygenic risk scores (PRSs) for internalizing phenotypes, including disorders (major depressive disorder, anxiety disorders) and traits (self-reported broad depression, suicide attempts, neuroticism), and internalizing symptoms during mid-adolescence. The sample included 918 females and 941 males (mean age = 15.1, SD = 0.6) of European ancestry from the Adolescent Brain Cognitive Development Study. We found no evidence for interactions between PRSs and pubertal maturation in sex-stratified models, or between PRSs and sex in combined-sex models. However, PRS main effects were observed, with the major depressive disorder PRS associated with greater internalizing symptoms across sexes (IRR = 1.143, 95%CI = 1.077-1.213, pFDR = 2.683E-05), whereas the broad depression PRS was significant only in females (IRR = 1.074, 95%CI = 1.020-1.130, pFDR = 0.047). In males, earlier pubertal timing (IRR = 0.901, 95%CI = 0.832-0.975, pFDR = 0.024) and faster pubertal tempo (IRR = 1.098, 95%CI = 1.024-1.178, pFDR = 0.049) were associated with higher internalizing symptoms. Overall, polygenic associations were more consistent, while pubertal associations were modest and contingent on measurement and analytic approach. These findings suggest that genetic and pubertal influences on adolescent internalizing symptoms operate through partially distinct pathways. By integrating longitudinal modeling with polygenic analyses, this study informs developmental models of adolescent internalizing psychopathology.

  • Open Access

    Genetic Exploration of Depression Onset in Females from Menarche to Menopause

    by Hannah Oppenheimer, Maria Viejo-Romero, Louise Schindler, Arielle Crestol, Dennis van der Meer, Christopher Rayner, Jared Gichohi Maina, Lars T. Westlye, Ann-Marie G de Lange, David M Howard, et al.

    Depression risk in females is markedly elevated during hormonal transitions such as menarche, the perinatal period, and menopause; yet the genetic basis of depression onset during these windows remains uncharacterized. We conducted GWAS meta-analyses (including the X chromosome) in females from Generation Scotland and UK Biobank, running the first GWAS of depression onset around menarche (ncases = 3,089; ncontrols = 25,558) and around natural menopause (ncases = 3,754; ncontrols = 14,079), and the largest female-specific GWAS of continuous age at onset of depression (N = 29,735). We identified one locus for depression onset around menarche and two for depression onset around menopause, including one mapping onto CDKAL1, a gene implicated in metabolic disorders, and no genome-wide significant findings for continuous age at onset. Genetic correlation analyses revealed moderate to strong positive correlations among depression onset around menarche, around menopause, and postpartum depression (rg = 0.47-0.95), suggesting possible shared genetic pathways of reproductive-related depressions. Mendelian randomization demonstrated a causal effect of earlier menarche on depression onset around menarche; by contrast, age at menopause did not causally influence depression onset around menopause. Together, these findings establish a partly shared and partly distinct genetic architecture across reproductive-related depression subtypes, implicate possible metabolic pathways in depression onset around menopause, and provide a genetic framework for understanding why hormonal transitions confer differential depression risk across the female lifespan. By shifting focus from lifetime risk to hormonally defined onset windows, this study advances a timing informed genetic framework for understanding sex differences in depression.

  • Open Access

    The genetic architecture of reproductive subtypes of depression in females

    by Arielle Crestol, Hannah Oppenheimer, Carina J. Koeppel, Claudia Barth

  • Open Access

    No causal links between estradiol and female’s brain and mental health using Mendelian randomization

    by Hannah Oppenheimer, Dennis van der Meer, Louise S. Schindler, Arielle Crestol, Alexey Shadrin, Ole A. Andreassen, Lars T. Westlye, Ann-Marie G. de Lange, Claudia Barth

    The role of estradiol in depression and Alzheimer's disease - brain disorders that disproportionately affect females - is debated. Results from observational studies are inconsistent and limited by confounding and reverse causation. To overcome these limitations, we perform two-sample Mendelian randomization. We run genome-wide association studies on sex-specific brain age gap, a proxy of brain health, and female-specific estradiol levels using data from the UK Biobank. We test for causal links between genetically-predicted factors related to estradiol exposure (estradiol levels in pre- and postmenopausal samples, reproductive span, age at menarche, age at menopause, number of childbirths) and brain age gap, Alzheimer's disease and depression as outcomes. We replicate our analyses on estradiol levels in males. Here, we find no significant associations between estradiol exposure and brain health across samples and robust methods, indicating an absence of constant causal effects and suggesting that hormonal fluctuations may drive links between estradiol and brain health.


  • Open Access

    Investigating Shared Cardiovascular Factors and Genetic Overlap of Pregnancy-Related Disorders, Major Depressive Disorder, and Alzheimer’s Disease

    by Hannah Oppenheimer, Alexey Shadrin, Jonas Ø. Andersen, Louise S. Schindler, Arielle Crestol, Ole A. Andreassen, Lars T. Westlye, Ann-Marie G. de Lange, Dennis van der Meer, Claudia Barth


  • Open Access

    Use of Mobile Sensing Data for Longitudinal Monitoring and Prediction of Depression Severity: Systematic Review

    by Rebeka Amin, Simon Schreynemackers, Hannah Oppenheimer, Milica Petrovic, Ulrich Hegerl, Hanna Reich

    Background: Depression is highly recurrent and heterogeneous. The unobtrusive, continuous collection of mobile sensing data via smartphones and wearable devices offers a promising approach to monitor and predict individual depression trajectories, distinguish illness states, and anticipate changes in symptom severity. Objective: This systematic review evaluates whether objective data from wearable devices and smartphones can (1) monitor and distinguish different states of depression, (2) predict changes in symptom severity, and (3) identify clinically relevant objective features for tracking and forecasting depression within diagnosed individuals. Methods: We searched PubMed and Web of Science databases for English-language studies (published 2012-2022) that used smartphone or wearable device data, included participants aged ≥14 years with a depression diagnosis, and collected continuous data for at least 12 weeks. Results: Out of 12,997 peer-reviewed articles, 9 original studies met the inclusion criteria, with sample sizes ranging from 45 to 2200 and durations of 12-52 weeks. Of the 9 studies, 3 used smartphone data, 1 used wearable device data, and 5 used both data types. Commonly collected variables were step count, distance moved, smartphone usage, call logs, sleep, heart rate, light exposure, and speech patterns. One study (11%) successfully differentiated between depressive states (worsening, relapse, or recovery). Six studies (67%) showed that mobile sensing data could predict depressive episodes or symptom severity. Four studies reported the predictive accuracy for depression using mobile sensing data from smartphones and wearable devices, ranging from 81% to 91%. Higher accuracy was achieved with personalized models or multimodal data. Conclusions: Real-time passive monitoring via wearable devices and smartphones holds promise for personalized self-management, but key gaps remain, such as a lack of longitudinal and long-term studies with data collection for 1 year or longer, studies with confirmatory parameters on an individual level, and studies with a strong correlation between parameters in individual patients to support clinical decision-making. Improvements in reporting standards are highly recommended to provide better-informed insights for clinicians. Throughout this process, there is a clear need to address various other issues, such as limited types of collected data, reliability, user adherence, and privacy concerns. Trial Registration: PROSPERO CRD42022355696; https://www.crd.york.ac.uk/PROSPERO/view/CRD42022355696


  • Open Access

    Sex differences in polygenic risk for sex-biased brain disorders: Associations with diagnostic status and brain age gap

    by Arielle Crestol, Dennis van der Meer, Nadine Parker, Ann-Marie G de Lange, Espen Hagen, Hannah Oppenheimer, Stener Nerland, Édith Breton, Christian K. Tamnes, Ole A. Andreassen, et al.

    Biological sex influences the prevalence and progression of several brain disorders, yet it remains unclear whether genetic risk interacts with sex in relation to case-control status or brain health. Using data from up to 220 836 females and 187 651 males in the UK Biobank (aged 39–81), we assessed how sex and polygenic risk scores (PRSs) for major depressive disorder (PRS_MDD), Alzheimer’s disease (PRS_AD), schizophrenia (PRS_SCZ), and Parkinson’s disease (PRS_PD) relate to case-control status and MRI-derived brain age gap (BAG) as a proxy of brain health. We tested for sex differences in PRSs and performed regression analyses examining associations between sex, PRSs, and both outcomes. We then compared models with sex-pooled or sex-specific PRSs to explore whether sex-specific PRSs improve predictive accuracy. PRS_SCZ was higher in females, while no other PRSs differed by sex. A significant PRS_AD-by-sex interaction revealed weaker associations with AD case-control status in males than females. Sex-pooled models outperformed sex-specific models for case-control status, apart from PRS_AD, where the female-only PRS_AD model outperformed the sex-pooled model. No sex-by-PRS interactions were significantly associated with BAG. However, male sex, higher PRS_MDD, higher PRS_AD, and lower PRS_PD were associated with higher BAG, indicative of an older brain age. BAG model performance did not differ between sex-pooled and sex-specific PRS models. In summary, while sex-specific PRSs currently offer limited value over sex-pooled scores, the superior performance of the female-specific PRS_AD model suggests that the value of sex-specific PRSs will likely grow with increased statistical power.

  • Open Access

    Shared Cardiovascular Factors and Genetic Overlap of Pregnancy-Related Disorders, Major Depressive Disorder, and Alzheimer’s Disease

    by Hannah Oppenheimer, Alexey Shadrin, Jonas Østerhaug Andersen, Louise Schindler, Arielle Crestol, Ole A. Andreassen, Lars T. Westlye, Ann-Marie G de Lange, Dennis van der Meer, Claudia Barth

    Background: Pregnancy-related disorders, such as hypertensive disorders of pregnancy (HDP) and postpartum depression, have consequences for maternal health, increasing risk for major depressive disorder (MDD) and Alzheimer’s disease (AD). Observational studies show intertwined pathophysiologies and shared cardiovascular factors. However, genetic links of cardiovascular factors with pregnancy-related disorders, MDD, and AD, as well as the genetic mechanisms between the disorders, have not been fully established. Methods: Using summary statistics from female-specific genome-wide association studies, we estimated genetic correlations and causal associations, using Mendelian randomization, between cardiovascular factors (C-reactive protein, HDL-cholesterol, LDL-cholesterol, and triglycerides), pregnancy-related disorders (HDP and postpartum depression), MDD, and AD. For significant associations, BMI, as a known confounder, was included in multivariable Mendelian randomization analyses. Further, we applied causal mixture models (MiXeR) to explore polygenic overlap between pregnancy-related disorders, MDD, and BMI.Results: We found widespread genetic correlations between cardiovascular factors, pregnancy-related disorders, and MDD. Using Mendelian randomization, higher triglycerides and lower HDL-cholesterol were causally linked to higher HDP risk, and higher LDL-cholesterol to higher AD risk. When including BMI, only the effect of triglycerides on HDP remained significant. Trivariate MiXeR estimated substantial polygenic overlap of pregnancy-related disorders with MDD and BMI.Conclusions: Using multiple genetic approaches, our findings indicate some shared cardiovascular factors associated with pregnancy-related disorders, MDD, and AD, partly driven by BMI. BMI should be further explored as a modifiable factor genetically linked to pregnancy-related, mental, and brain disorders. Our findings highlight the relevance of early prevention of genetically interconnected disorders across the female lifespan.

  • Open Access

    No Causal Links Between Lifetime Estradiol Exposure and Female’s Brain and Mental Health – A Mendelian Randomization Study

    by Hannah Oppenheimer, Dennis van der Meer, Louise Schindler, Arielle Crestol, Lars T. Westlye, Ann-Marie G de Lange, Claudia Barth

    Estradiol, the predominant sex steroid in females, has been implicated in the development of depression and Alzheimer’s disease – two disorders that disproportionately affect females. Yet, while some studies suggest protective effects of estradiol on brain health and mental health, results are inconsistent partly due to methodological challenges of observational studies such as confounding and reverse causation. In this preregistered study, we examined whether estradiol levels and factors related to lifetime estradiol exposure are causally linked to brain age gap (predicted brain age relative to chronological age), AD risk, and depression risk in females. The factors related to estradiol exposure included reproductive span, age at menarche, age at menopause, number of childbirths, oral contraceptive use, HRT use, history of hysterectomy, and history of oophorectomy. To overcome some challenges of observational studies, we tested for causal associations by conducting two-sample Mendelian randomization analyses using female-specific summary statistics from previously conducted and newly run genome-wide association studies (GWAS). This included running the first female-specific GWAS on brain age gap and a GWAS on estradiol levels. No significant causal associations were found between estradiol levels, or any factors related to lifetime estradiol exposure and brain age gap, AD, or depression. Therefore, the results do not support causal links of estradiol with mental and brain health in females. Future studies should assess other influencing factors, as well as implement sex-specific, causal frameworks to examine potential effects of hormonal fluctuations and periods of increased susceptibility to sex steroids such as the perimenopausal period.